<i id='39AB7EF404'><strike id='39AB7EF404'><tt id='39AB7EF404'><pre id='39AB7EF404'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular
read more
Underamicroscope,humanprostatecancercells,colorizedinblue,appearinanairbubble.AdobeAnearly-stageclin
read more
EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3
read moreAdoseofmethadoneKevinD.Liles/APThefederalgovernmentisunveilingnewregulationsmeanttomodernizemethadon
